Esperion Therapeutics (ESPR) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Esperion Therapeutics Revenue Highlights

Latest Revenue (Y)

$403.13M

Latest Revenue (Q)

$87.31M

Main Segment (Y)

Collaboration Revenue

Esperion Therapeutics Revenue by Period

Esperion Therapeutics Revenue by Year

Date	Revenue	Change
2025-12-31	$403.13M	21.31%
2024-12-31	$332.31M	185.66%
2023-12-31	$116.33M	54.14%
2022-12-31	$75.47M	-3.79%
2021-12-31	$78.45M	-65.52%
2020-12-31	$227.55M	53.37%
2019-12-31	$148.36M	-19.57%
2018-12-31	$184.47M	100.00%
2017-12-31	-	100.00%
2016-12-31	-	100.00%
2015-12-31	-	100.00%
2014-12-31	-	-100.00%
2013-12-31	$4.98B	100.00%
2012-12-31	-	100.00%
2011-12-31	-	100.00%
2002-12-31	-	100.00%
2001-12-31	-	-100.00%
2000-12-31	$2.00K	100.00%
1999-12-31	-	-

Esperion Therapeutics generated $403.13M in revenue during NA 2025, up 21.31% compared to the previous quarter, and up 177.17% compared to the same period a year ago.

Esperion Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-09-30	$87.31M	5.98%
2025-06-30	$82.39M	26.76%
2025-03-31	$65.00M	-5.96%
2024-12-31	$69.11M	33.86%
2024-09-30	$51.63M	-30.07%
2024-06-30	$73.83M	-46.39%
2024-03-31	$137.74M	327.09%
2023-12-31	$32.25M	-5.06%
2023-09-30	$33.97M	31.73%
2023-06-30	$25.79M	5.99%
2023-03-31	$24.33M	29.29%
2022-12-31	$18.82M	-0.85%
2022-09-30	$18.98M	0.74%
2022-06-30	$18.84M	0.03%
2022-03-31	$18.84M	22.30%
2021-12-31	$15.40M	6.88%
2021-09-30	$14.41M	-64.56%
2021-06-30	$40.66M	409.64%
2021-03-31	$7.98M	-17.22%
2020-12-31	$9.64M	151.45%
2020-09-30	$3.83M	-98.19%
2020-06-30	$212.24M	11434.57%
2020-03-31	$1.84M	87.37%
2019-12-31	$982.00K	0.10%
2019-09-30	$981.00K	-0.10%
2019-06-30	$982.00K	-99.32%
2019-03-31	$145.42M	-21.17%
2018-12-31	$184.47M	100.00%
2018-09-30	-	100.00%
2018-06-30	-	100.00%
2018-03-31	-	100.00%
2017-12-31	-	100.00%
2017-09-30	-	100.00%
2017-06-30	-	100.00%
2017-03-31	-	100.00%
2016-12-31	-	100.00%
2016-09-30	-	100.00%
2016-06-30	-	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	100.00%
2012-06-30	-	100.00%
2012-03-31	-	100.00%
2003-09-30	-	100.00%
2003-06-30	-	100.00%
2003-03-31	-	100.00%
2002-12-31	-	100.00%
2002-09-30	-	100.00%
2002-06-30	-	100.00%
2002-03-31	-	100.00%
2001-12-31	-	100.00%
2001-09-30	-	-100.00%
2001-06-30	$1.00K	-
2001-03-31	$1.00K	-
2000-12-31	$1.00K	-
2000-09-30	$1.00K	-
2000-06-30	$1.00K	100.00%
2000-03-31	-	-

Esperion Therapeutics generated $87.31M in revenue during Q3 2025, up 5.98% compared to the previous quarter, and up 118.25% compared to the same period a year ago.

Esperion Therapeutics Revenue Breakdown

Esperion Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Product	$159.57M	$115.72M	$78.33M	$55.86M	-
Collaboration Revenue	$243.57M	$216.59M	$38.00M	$19.61M	$38.40M
Royalty Revenue From DSE	-	-	-	-	$9.90M

Esperion Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Collaboration Revenue (60.42%), and Product (39.58%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Product	$43.72M	$40.66M	$40.27M	$34.91M	$59.86M	$31.11M	$24.76M	$20.76M	$20.25M	$20.29M	$17.03M	$14.97M	$12.19M	$8.17M	-	-	-	-	-	-
Collaboration Revenue	$124.72M	$46.65M	$42.11M	$30.08M	$83.08M	$20.53M	$112.98M	$11.49M	$13.72M	$5.49M	$7.30M	$3.85M	$5.02M	$5.26M	$5.48M	$3.21M	$3.51M	$30.05M	$1.63M	$1.47M
Royalty Revenue And Product Sales Bulk Tablets	-	-	-	-	-	-	-	-	-	-	-	-	$4.40M	$5.00M	$5.30M	$3.30M	-	-	-	-
Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.00M	-	-
Product Sales Bulk Tablets Nilemdo And Nustendi	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.60M	-

Esperion Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Collaboration Revenue (74.04%), and Product (25.96%).

Esperion Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
SNDL	SNDL	$909.01M	$197.75M
EBS	Emergent BioSolutions	$742.90M	$231.10M
ESPR	Esperion Therapeutics	$403.13M	$87.31M
RGNX	REGENXBIO	$170.44M	$29.73M
SIGA	SIGA	$94.60M	$2.62M
AQST	Aquestive Therapeutics	$44.55M	$10.00M
ABSI	Absci	$4.53M	$378.00K
CRVS	Corvus Pharmaceuticals	-	-
VTYX	Ventyx Biosciences	-	-
OLMA	Olema Pharmaceuticals	-	-
OFIX	Orthofix Medical	-	$205.63M

ESPR Revenue FAQ

What is Esperion Therapeutics’s yearly revenue?

Esperion Therapeutics's yearly revenue for 2025 was $403.14M, representing an increase of 21.31% compared to 2024. The company's yearly revenue for 2024 was $332.31M, representing an increase of 185.66% compared to 2023. ESPR's yearly revenue for 2023 was $116.33M, representing an increase of 54.14% compared to 2022.

What is Esperion Therapeutics’s quarterly revenue?

Esperion Therapeutics's quarterly revenue for Q3 2025 was $87.31M, a 5.98% increase from the previous quarter (Q2 2025), and a 69.10% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $82.38M, a 26.76% increase from the previous quarter (Q1 2025), and a 11.58% increase year-over-year (Q2 2024). ESPR's quarterly revenue for Q1 2025 was $65M, a -5.96% decrease from the previous quarter (Q4 2024), and a -52.81% decrease year-over-year (Q1 2024).

What is Esperion Therapeutics’s revenue growth rate?

Esperion Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 246.53%, and for the last 5 years (2021-2025) was 413.89%.

What are Esperion Therapeutics’s revenue streams?

Esperion Therapeutics's revenue streams in c 25 are Product, and Collaboration Revenue. Product generated $159.57M in revenue, accounting 39.58% of the company's total revenue, up 37.89% year-over-year. Collaboration Revenue generated $243.57M in revenue, accounting 60.42% of the company's total revenue, up 12.46% year-over-year.

What is Esperion Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Esperion Therapeutics was Collaboration Revenue. This segment made a revenue of $243.57M, representing 60.42% of the company's total revenue.